MOORESTOWN, N.J., March 01, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company providing medication safety solutions for health plans and provider groups, has successfully implemented its first payer-based Care Transitions program focused on medication risk mitigation following discharge from a hospital or post-acute care facility. The purpose is to provide comprehensive medication reconciliation and optimization to prevent readmission due to medication problems.
According to TRHC Chairman and CEO, Calvin H. Knowlton, PhD, this member population is typically on multiple medications to treat chronic diseases. “Polypharmacy raises the chance of dangerous multi-drug interactions and serious side effects that can lead to hospital readmissions,” said Knowlton. “Our goal is to reduce risk for an adverse drug event by personalizing the member’s medication regimen to optimize pharmacotherapy treatment. We are excited to include our Medication Risk Mitigation Software Platform, MedWise Advisor®, as well as our personalized Medication Decision Support processes on behalf of the Plan members.”
The program, which launched January 1, 2017, provides a comprehensive medication reconciliation performed by Tabula Rasa HealthCare (TRHC) pharmacists in the health plan members’ homes within the first week following notification of discharges. Pharmacists perform a medication risk mitigation screening using the TRHC MedWise Advisor® software to determine medication risk. The TRHC pharmacists consult with the patient’s primary physician to discuss actual and potential risks with the goal of avoiding negative consequences. Members are provided information and documentation regarding their reconciled medication regimen and an action plan to discuss with their prescriber. As one member commented, “It was a learning experience; it made me feel like I had more control over my life instead of just doing what I was told. It made me feel like I had control over how I felt.”
TRHC’s proprietary science and technology Medication Risk Mitigation products and services perform 360-degree reviews and safety assessments of complex medication regimens, providing an innovative, alternative approach to personalized pharmacotherapy. The objective is to optimize medication use thereby improving outcomes, including reduction in falls, emergency room visits, and medication-related hospitalizations.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.trhc.com.
Contact: Media Dianne Semingson [email protected] T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]


Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 



